Navigation Links
The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
Date:9/9/2008

TUSTIN, Calif., Sept. 9 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, today announced that The Wall Street Transcript (http://www.twst.com) features an interview with Mr. Gary Dreher, President and CEO of AMDL, Inc., in its Healthcare Services report for September 9, 2008. A copy of the interview is available in the Healthcare Services section of The Wall Street Transcript located at http://www.twst.com .

In the interview, Mr. Dreher discusses AMDL's focus on the $100B China market and the Company's distribution expansion throughout the region. Additionally, he covers the AMDL's breakthrough DR-70(R) ELISA (FDP) cancer diagnostic test kit, which was recently cleared by the US FDA for the monitoring of colorectal cancer; as well as the company's top-selling products developed through its wholly owned subsidiary Jade Pharmaceuticals.

According to Mr. Dreher, "AMDL is a growth company with significant potential and a key priority for the Company is effectively communicating our story to existing and potential investors. This interview provided us with a perfect opportunity to outline our current market environment, recent business developments, and ongoing goals and strategies in a straightforward and candid way for the investment community and we are excited to be featured."

The Wall Street Transcript (TWST) conducts in-depth interviews of CEOs of public companies to provide an unscripted, first-hand perspective for TWST subscribers, which includes mutual fund managers, research analysts, money managers, investment brokers and individual investors. AMDL's interview with The Wall Street Transcript is published and available to the public immediately. To view this interview visit http://www.twst.com.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products.

About Jade Pharmaceuticals Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
2. AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
3. Dow AgroSciences Success Presented to Wall Street
4. Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript
5. Main Street Gourmet Launches New Probiotic Muffins
6. Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
9. Attagenes Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods
10. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
11. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... spending the past two years building a state-of-the-art technology which consolidates ... this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) who ... vis a vis their members, under their own brand. Three recent ... ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is pleased to ... and scientific instruments. This year’s symposium, organized by the Pittcon 2018 program chair, ... Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high throughput IMS-MS ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and ... programming through a series of upcoming panels and events. The partnership culminates with the ... Roosevelt Hotel in New York City. , “With our experience in producing the Immuno-Oncology ...
(Date:8/14/2017)... , ... August 14, 2017 , ... ... and performing antibodies. Key researchers in the antibody community have recently come together ... consistency for antibodies in the laboratory. , The team at ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):